RT Journal Article SR Electronic T1 International Union of Basic and Clinical Pharmacology. LXXXIV: Leukotriene Receptor Nomenclature, Distribution, and Pathophysiological Functions JF Pharmacological Reviews JO Pharmacol Rev FD American Society for Pharmacology and Experimental Therapeutics SP 539 OP 584 DO 10.1124/pr.110.004184 VO 63 IS 3 A1 Magnus Bäck A1 Sven-Erik Dahlén A1 Jeffrey M. Drazen A1 Jilly F. Evans A1 Charles N. Serhan A1 Takao Shimizu A1 Takehiko Yokomizo A1 G. Enrico Rovati YR 2011 UL http://pharmrev.aspetjournals.org/content/63/3/539.abstract AB The seven-transmembrane G protein-coupled receptors activated by leukotrienes are divided into two subclasses based on their ligand specificity for either leukotriene B4 or the cysteinyl leukotrienes (LTC4, LTD4, and LTE4). These receptors have been designated BLT and CysLT receptors, respectively, and a subdivision into BLT1 and BLT2 receptors and CysLT1 and CysLT2 receptors has been established. However, recent findings have also indicated the existence of putative additional leukotriene receptor subtypes. Furthermore, other ligands interact with the leukotriene receptors. Finally, leukotrienes may also activate other receptor classes, such as purinergic receptors. The aim of this review is to provide an update on the pharmacology, expression patterns, and pathophysiological roles of the leukotriene receptors as well as the therapeutic developments in this area of research.